Windgap Medical has forged a partnership with ALK-Abello to commercialize the former’s epinephrine autoinjector (EAI) for the treatment of anaphylactic shock.
As per the agreement, ALK-Abello will have exclusive, worldwide sales and distribution rights for the Windgap epinephrine autoinjector. For this, ALK-Abello will be making up-front, technical, and sales milestone payments plus tiered royalties on net sales in the US and a split of net profit for products sold outside of the country to Windgap Medical.
Epinephrine autoinjectors are used for the emergency treatment of acute allergic reactions (anaphylaxis), which are caused by exposure to certain foods, or by exposure to venom from wasp or bee stings.
Windgap Medical expects the market for epinephrine autoinjectors in the US to cross $1 billion annually, with a large unmet need that may facilitate significant market growth.
The company and its manufacturing collaborators are marketing its ANDIPen wet/dry autoinjector platform with the first product using the platform being epinephrine for the treatment of anaphylaxis.
According to Windgap Medical, an epinephrine autoinjector is designed to address various unmet patient needs such as portability, ease-of-use, temperature stability, and a long shelf-life.
Chris Stepanian – Windgap Medical CEO and co-founder said: “Windgap is excited to be working with ALK, a world-leader in the treatment of allergy with a strong understanding of the world-wide EAI market, to help commercialize our product. Our teams are working well in partnership to support that effort.
“Windgap has worked hard to assemble a world-class team to commercialize our epinephrine autoinjector. I believe the global market to be sizable and significantly under addressed. In addition to our partnership with ALK, we have strong support through a strategic investment by Molex Ventures.
“Molex represents one of our major manufacturing collaborators who is investing along-side our Series B lead investor Shepherd Kaplan Krochuk.”
Windgap Medical said that its products are yet to be reviewed by the FDA but the plans to seek approval, first, for its epinephrine autoinjector for anaphylaxis.